Do statins cause dementia, and does CoQ10 help? What the new study can and can't show
A study published on 29 October linked statin use in White adults aged 40 and older to about twice the risk of diagnosed dementia. It was observational. Randomized trials with more than 100,000 people found no rise in dementia or cognitive problems. We found no trial of CoQ10 for dementia in people taking a statin, and its trials for statin muscle aches disagree.
Everstack Evidence Team. Sources checked 1 November 2026.
The study people are sharing
On 29 October 2026, Frontiers in Pharmacology published a study by South Korean researchers comparing adults who started a statin with non-users in two big health databases: the US All of Us program (83,355 people) and UK Biobank (173,282 people). Everyone was 40 or older and self-identified as White. After statistical weighting, statin users had about 2.2 times (All of Us) and 2.5 times (UK Biobank) the risk of a recorded dementia diagnosis (hazard ratios). In All of Us, that meant about 65 versus 31 new diagnoses per 10,000 person-years. High-intensity statins were linked to a 14% higher risk than lower-intensity ones [1].
Looking for a mechanism without direct CoQ10 data, the authors used blood levels of COQ7, a protein involved in making CoQ10, measured once in 38,553 UK Biobank participants. Statin users had slightly lower COQ7, lower COQ7 went with more dementia, and that pathway accounted for 8.2% of the association. The authors call this CoQ10-pathway finding exploratory and hypothesis-generating, and write that their findings "warrant further investigation before informing clinical decisions about statin therapy." Funding came from Korean government research grants and Chungbuk National University; the authors declared no conflicts of interest [1].
On X, on 31 October, Shawn Baker, a physician with about 379,000 followers, wrote that it "linked statin use to roughly double the risk of dementia," while noting in the same post that observational data cannot prove causation [2]. On 30 October, Joel Kahn, a doctor whose X profile describes a focus on heart disease prevention, posted: "Looks like higher doses of coQ10 are mandatory!" [3] We grade that supplement claim below; we grade claims, not people.
Why this kind of study can't settle it
People who get prescribed statins differ from people who don't. Before weighting, statin users in All of Us were far more likely to have high blood pressure (49.5% vs 16.1%), diabetes (18.4% vs 3.7%) and coronary artery disease (17.5% vs 3.6%) [1], conditions themselves linked to dementia. Weighting balanced what was measured, but the authors note that confounding by indication may remain, that smoking and alcohol were left out of the main analyses, and that "non-users" were people with no statin prescription during the entire follow-up, a definition that uses future information and can bias the comparison [1].
Randomized trials avoid that. A 2025 meta-analysis of 15 randomized trials with 139,169 participants found dementia or cognitive impairment in 1.33% of people on lipid-lowering drugs versus 1.36% on control (odds ratio 0.96, 95% CI 0.74 to 1.26) [4]. A Cochrane review of two placebo-controlled statin trials in 26,340 people at vascular risk found no difference on five cognitive tests, rated high-quality evidence [5]. A 2026 meta-analysis of 42 trials of cholesterol-lowering drugs (150,405 people) found no increase in neurocognitive events, including in the statin trials alone [6]. The limit: trial follow-up averaged 34.5 months in the 2025 analysis [4], so trials can't rule out effects that take decades to appear.
Other observational research points the opposite way. A 2025 meta-analysis of 55 observational studies with more than 7 million people linked statin use to a 14% lower dementia risk (hazard ratio 0.86) [7]. That doesn't prove protection either. And the worry isn't new: the 2012 FDA-approved label for atorvastatin (Lipitor) noted rare postmarketing reports of memory loss or confusion, reported for all statins, generally not serious and reversible after stopping, with onset from 1 day to years and resolution in a median of 3 weeks [8].
The part that is true about CoQ10
Statins inhibit a step in the pathway the body uses to make both cholesterol and CoQ10 [16]. A meta-analysis of placebo-controlled trials found that statins lower blood (plasma) CoQ10 by an average of 0.44 micromoles per liter [9]. Blood is not muscle, though. In a Danish study of 64 people on simvastatin and 20 untreated people with high cholesterol, CoQ10 inside muscle was similar across groups, including in those with muscle aches [10]. In a 2026 randomized trial in 40 older adults living independently (average age 74), 400 mg a day for 12 weeks raised blood CoQ10 but didn't change muscle CoQ10 or mitochondrial function; one author consults for Pharma Nord, a company that sells CoQ10 supplements [11].
Does CoQ10 ease statin muscle aches?
The trials disagree. A 2018 meta-analysis of 12 trials (575 patients) found less muscle pain, weakness, cramps and tiredness with CoQ10 [12]. Three others found no significant benefit: 6 trials (302 patients) in 2015 [13]; 7 trials (321 patients) in 2020 [14]; and the pain analysis of a 2021 review, 4 trials (220 patients) [15]. The newest, from 2025 (7 trials, 389 patients), found pain about 1 point lower on a 0 to 10 scale (95% CI 0.03 to 1.88 points lower), but results varied widely between trials, and leaving out any one of four of the trials made the result no longer statistically significant [16].
One carefully designed trial first confirmed who really had statin pain. Of 120 people with a history of statin aches, 41 developed pain on simvastatin but not on placebo in a blinded test. They then took the statin with 600 mg a day of CoQ10 (as ubiquinol) or a placebo for 8 weeks. Pain rose either way, and marginally more people reported pain on CoQ10 (14 of 20 vs 7 of 18, p=0.05). The trial was NIH-funded; its senior author disclosed research support, consulting or speaker fees from statin makers including Pfizer, Merck and AstraZeneca [17].
Also: in 19 large blinded trials (123,940 people), 27.1% on a statin and 26.6% on placebo reported muscle pain or weakness, and the authors estimate that more than 90% of those reports in statin users were not caused by the statin [18]. Several of those authors disclosed industry grants or fees [18]. NIH's complementary health center, on a page last updated in 2019, says the overall evidence does not support CoQ10 for statin muscle pain [19], and Harvard Health reports that the American Heart Association and American College of Cardiology recommend against routine CoQ10 use for statin muscle symptoms [20].
CoQ10 and dementia: no trial in statin users
We found no randomized trial testing whether CoQ10 changes dementia risk in people taking statins. A 2023 systematic review by Spanish researchers found that studies of CoQ10 in people with Alzheimer's disease, other dementias or mild cognitive impairment were inconclusive, though rodent studies looked more promising [21]. The COQ7 finding is about the body's own CoQ10 production and says nothing about whether a pill would change anyone's risk [1].
Our grades for the CoQ10 claims
Each row grades the published evidence for CoQ10 for one use people are talking about, on our usual A to D scale. We don't sell CoQ10, and none of these is a claim we make.
| Claim | Grade | Why |
|---|---|---|
| CoQ10 eases muscle aches in people taking a statin | C (mixed) | Small, short trials. Meta-analyses from 2018 and 2025 found less pain [12][16]; three others found no significant benefit [13][14][15]. The trial that first confirmed the statin caused the pain found no benefit at 600 mg a day [17]. Where a benefit showed up in 2025, it was about 1 point on a 10-point scale and fragile [16]. |
| CoQ10 lowers dementia risk in people taking a statin | D (no trials in statin users) | We found no randomized trial testing it. The new study measured a protein involved in making CoQ10, not CoQ10 itself, and not supplements [1]. Studies in people who already had dementia or mild cognitive impairment were inconclusive [21]. |
| CoQ10 refills muscle CoQ10 or boosts mitochondria | D (early data, mostly against) | Muscle CoQ10 was similar in simvastatin users and untreated people [10]. In one 12-week trial in 40 older adults, 400 mg a day raised blood levels only, with no change in muscle CoQ10 or mitochondrial function [11]. |
A grade rates the published evidence for this molecule for this use, not any product. A low grade doesn't mean the molecule is harmful. This is not medical advice.
What we'd do
If you take a statin, this study is not a reason to stop or change it on your own; its authors say it shouldn't drive treatment decisions yet [1]. MedlinePlus warns that stopping a statin on your own can lead to a serious problem or, in rare cases, death, and advises talking with your prescriber first [22]. If dementia risk worries you, bring it to that conversation.
If you get muscle aches on a statin, tell your clinician. They can order a blood test for muscle damage, and switching to a different statin can help [22].
CoQ10 is your call. It isn't proven for statin aches, and nothing in people shows it protects memory. No serious side effects have been reported; mild ones include insomnia and stomach upset. It may interact with the blood thinner warfarin and with insulin, and may not be compatible with some cancer treatments [19]. Trials used 100 to 600 mg a day for 1 to 3 months [16]. If you try it, tell your prescriber.
Disclosure
Everstack doesn't sell CoQ10 or any statin, and this page links to no product. Nothing here claims that any supplement treats, cures or prevents any disease.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Sources
- Lee DH, Park YA, Kim JS, Yee J, Han JM, Gwak HS. Front Pharmacol. 2026;17:1915633. Statin therapy and dementia risk in All of Us and UK Biobank, with COQ7 mediation analysis (published 29 Oct 2026). doi.org/10.3389/fphar.2026.1915633
- Baker S. Post on X, 31 Oct 2026 (quoted as posted). x.com/SBakerMD/status/2116555059420913956
- Kahn J. Post on X, 30 Oct 2026 (quoted as posted). x.com/drjkahn/status/2116110014607716750
- Reddin C et al. Age Ageing. 2025;54(8):afaf219. Meta-analysis of randomized trials, lipid-lowering therapy and dementia or cognitive impairment, 139,169 participants. PMID 40794911. doi.org/10.1093/ageing/afaf219
- McGuinness B et al. Cochrane Database Syst Rev. 2016;(1):CD003160. Statins for the prevention of dementia. PMID 26727124. doi.org/10.1002/14651858.CD003160.pub3
- Li K et al. Front Neurol. 2026;17:1696228. Meta-analysis of 42 randomized trials, cholesterol-lowering drugs and neurocognitive function. PMID 41716550. doi.org/10.3389/fneur.2026.1696228
- Westphal Filho FL et al. Alzheimers Dement (N Y). 2025;11(1):e70039. Meta-analysis of 55 observational studies, statin use and dementia. PMID 39822593. doi.org/10.1002/trc2.70039
- US FDA. Lipitor (atorvastatin) prescribing information, 2012 revision, section 6.2: postmarketing reports of cognitive impairment, which the label says were reported for all statins. www.accessdata.fda.gov/drugsatfda_docs/label/2012/020702s060lbl.pdf
- Banach M et al. Pharmacol Res. 2015;99:329-336. Meta-analysis, statin therapy and plasma CoQ10. PMID 26192349. doi.org/10.1016/j.phrs.2015.07.008
- Dohlmann TL et al. J Clin Endocrinol Metab. 2019;104(7):2501-2508. LIFESTAT: muscle CoQ10 in simvastatin users with and without myalgia. PMID 30299473. doi.org/10.1210/jc.2018-01185
- Schmücker M et al. GeroScience. 2026;48(6):8049-8063. Randomized trial, 400 mg CoQ10 for 12 weeks in 40 older adults. PMID 41604113. doi.org/10.1007/s11357-025-02068-9
- Qu H et al. J Am Heart Assoc. 2018;7(19):e009835. Meta-analysis, 12 trials, CoQ10 and statin-associated muscle symptoms. PMID 30371340. doi.org/10.1161/JAHA.118.009835
- Banach M et al. Mayo Clin Proc. 2015;90(1):24-34. Meta-analysis, 6 trials, CoQ10 and statin myopathy. PMID 25440725. doi.org/10.1016/j.mayocp.2014.08.021
- Kennedy C, Köller Y, Surkova E. Atherosclerosis. 2020;299:1-8. Meta-analysis, CoQ10, statin myalgia and adherence. PMID 32179207. doi.org/10.1016/j.atherosclerosis.2020.03.006
- Wei H et al. Ir J Med Sci. 2022;191(2):719-725 (online 2021). Meta-analysis, CoQ10 and statin-induced myopathy. PMID 33999383. doi.org/10.1007/s11845-021-02651-x
- Kovacic S, Habicht SD, Eckert GP. J Nutr Sci. 2025;14:e72. Meta-analysis, 7 trials, CoQ10 and muscle pain on statins. PMID 41158831. doi.org/10.1017/jns.2025.10043
- Taylor BA et al. Atherosclerosis. 2015;238(2):329-335. Randomized trial of CoQ10 in confirmed statin myalgia (with disclosures). PMID 25545331. doi.org/10.1016/j.atherosclerosis.2014.12.016
- Cholesterol Treatment Trialists' Collaboration. Lancet. 2022;400(10355):832-845. Statins and muscle symptoms, 19 placebo-controlled trials (with disclosures). PMID 36049498. doi.org/10.1016/S0140-6736(22)01545-8
- NIH National Center for Complementary and Integrative Health. Coenzyme Q10 (last updated January 2019). www.nccih.nih.gov/health/coenzyme-q10
- Harvard Health Publishing. CoQ10: Should you take this popular supplement if you're on a statin? www.health.harvard.edu/medications-and-treatments/coqsub10sub-should-you-take-this-popular-supplement-if-youre-on-a-statin
- Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E et al. Antioxidants (Basel). 2023;12(2):533. Coenzyme Q10 and dementia: a systematic review. PMID 36830090. doi.org/10.3390/antiox12020533
- MedlinePlus (US National Library of Medicine). Statins. medlineplus.gov/statins.html